Cardamonin Inhibits Angiogenesis by mTOR Downregulation in SKOV3 Cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
• Hypoxia, a low-oxygen environment, is a common feature of solid tumors and stimulates angiogenesis.
• The mammalian target of rapamycin (mTOR) signaling pathway plays a vital role in regulating cellular responses to hypoxia, including angiogenesis.

Purpose of the Study:

• To investigate the antiangiogenic effects of cardamonin in ovarian cancer cells under hypoxic conditions.
• To elucidate the molecular mechanisms underlying cardamonin's antiangiogenic activity, focusing on mTOR signaling and key angiogenic factors.

Main Methods:

• Utilized SKOV3 ovarian cancer cells exposed to CoCl2 to mimic hypoxic conditions.
• Assessed the effects of cardamonin and rapamycin on cell proliferation, mRNA expression of vascular endothelial growth factor (VEGF), and protein expression of hypoxia-inducible factors (HIF-1α, HIF-2α), VEGF, phosphorylated mTOR, and ribosomal S6 kinase 1 (p-S6K1).
• Evaluated the antiangiogenic potential using a chicken embryo allantois membrane (CAM) model.

Main Results:

• Cardamonin demonstrated antiproliferative effects on both normal and hypoxic SKOV3 cells.
• Cardamonin and rapamycin inhibited VEGF mRNA expression under both normoxic and hypoxic conditions.
• Cardamonin significantly reduced the protein expression of HIF-1α, HIF-2α, VEGF, p-mTOR, and p-S6K1 in hypoxic SKOV3 cells.
• Angiogenesis in the CAM model was suppressed by cardamonin-treated SKOV3 cell medium.

Conclusions:

• Cardamonin inhibits hypoxia-induced angiogenesis in ovarian cancer cells by downregulating HIF-α and VEGF protein expression.
• The antiangiogenic effect of cardamonin is partially mediated through the inhibition of the mTOR signaling pathway.
• Cardamonin shows promise as a potential therapeutic agent for inhibiting angiogenesis in ovarian cancer.